Filing Flows › Health Care › PAVmed (PAVM)
PAVmed (PAVM) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 13, 2026 · PAVmed (PAVM) Q2 2026 earnings results →
Q2 2026 Revenue up 450% year over year to $33K
PAVmed made $33K in Q2 2026 (+450% Y/Y). Operating margin n/m, net loss $6.6M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 13, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $33K in Q2 2026, up 450% year over year and up 50% from the previous quarter.
Operating costs exceeded revenue by $7.0M, an operating margin of -21278.8%. Total costs grew 49% against revenue growth of 450%. The fastest-growing cost line was Cost of revenue (+198%). The quarter ended with a net loss of $6.6M, wider than the previous quarter's $1.1M loss. Minority interests bore $1.2M of it: to shareholders the quarter was a loss of $5.4M.
Operating cash flow was −$2.7M. Non-cash charges added back $19K of depreciation and amortization and $917K of share-based compensation. Working capital and other items added $3.0M. Capital expenditures of $13K exceeded it, leaving free cash flow of −$2.7M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 13, 2026 | $33K | +450% | n/m | −$6.6M | −$2.7M |
| Q1 2026 | 10-Q | May 14, 2026 | $22K | +175% | n/m | −$1.1M | −$2.6M |
| Q4 2025 | 10-K | Mar 27, 2026 | $52K | +420% | n/m | −$2.8M | −$1.6M |
| Q3 2025 | 10-Q | Nov 12, 2025 | $5K | -100% | n/m | −$6.0M | −$896K |
| Q2 2025 | 10-Q | Aug 14, 2025 | $6K | -99% | n/m | −$12.3M | −$1.2M |
| Q1 2025 | 10-Q | May 15, 2025 | $8K | -99% | n/m | $18.6M | −$1.6M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About PAVmed
Unless the context otherwise requires, “ we ” , “ us ” , and “ our ” , the “ Company ” and “ PAVmed ” refer to PAVmed Inc. and its subsidiaries, including its subsidiary Lucid Diagnostics Inc. (Nasdaq:LUCD) ( “ Lucid Diagnostics ” or “ Lucid ” ) and its majority-owned subsidiary Veris Health Inc. ( “ Veris Health ” or “ Veris ” ). PAVmed is a diversified commercial-stage life sciences company operating in the medical device, diagnostics, and digital health sectors. It operates through multiple independently financed subsidiaries under a shared services model. The Company’s strategy is to advance and commercialize innovative healthcare technologies through its subsidiaries while maintaining flexibility to structure financing at either the PAVmed level or within its subsidiaries.
In its own words, from its 10-K, filed Mar 27, 2026.
PAVmed against its Surgical & Medical Instruments & Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +450% against the peers' median +5%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| PAVM PAVmed | Q2 2026 | $33K | +450% | n/m |
| MDLN Medline | Q3 2026 | $7.9B | +10% | 6.4% |
| MMM 3M | Q3 2026 | $6.6B | +1% | 23.7% |
| SYK Stryker | Q3 2026 | $6.5B | +8% | 15.9% |
| BSX Boston Scientific | Q3 2026 | $5.1B | +1% | 16.1% |
| BDX Becton Dickinson | Q3 FY26 | $5.0B | +5% | 13.3% |
| BAX Baxter International | Q3 2026 | $3.0B | +5% | 7.6% |
| SOLV Solventum | Q3 2026 | $1.9B | -7% | 3.5% |
| RMD ResMed | Q1 FY27 | $1.4B | +6% | 32.0% |
Source: PAVmed 10-Q on SEC EDGAR · CIK 1624326 · Surgical & Medical Instruments & Apparatus
13F: who owns PAVM and who is buying
More on PAVM
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results